Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CPI-444 · 1 trial · 1 indication
Area under the plasma concentration-time curve (AUC) from time zero to infinity
AUC from time zero to the last quantifiable concentration
Percentage of AUC0-∞ that was due to extrapolation from the last quantifiable concentration to infinity
| Arm | Type | Description |
|---|---|---|
| Sequence ABC | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed). |
| Sequence BCA | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted). |
| Sequence CAB | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted). |
| Name | Type | Description |
|---|---|---|
| CPI-444 Capsules | DRUG | 100mg Capsule |
| CPI-444 Tablets | DRUG | 100mg Tablets |
Inclusion Criteria: 1. Males or females, of any race, 18 to 65 years of age, inclusive, at Screening. 2. Body mass index between 18.5 and 32.0 kg/m2, inclusive, at Screening. 3. In good health. 4. Females will be nonpregnant and nonlactating, and females of childbearing potential and males will agr...
CPI-444 is an investigational small molecule being studied in healthy subjects. It is currently in Phase 1 clinical development. The drug is being evaluated for its pharmacokinetic profile, specifically how it is absorbed and processed by the body when taken as a tablet formulation.
CPI-444 is being developed by Corvus Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol CRVS. Corvus is conducting clinical trials to evaluate the drug's properties in healthy volunteers.
CPI-444 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is currently being studied in a Phase 1 trial to evaluate its pharmacokinetics in healthy subjects.
CPI-444 has one completed clinical trial, identified as NCT03237988. This Phase 1 study evaluated the pharmacokinetics of a new tablet formulation of CPI-444 in fed and fasted healthy male and female subjects. The trial was conducted in the United States with 24 participants.
CPI-444 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied in healthy subjects to evaluate its pharmacokinetic properties, but it has not yet received regulatory approval for any medical use.